Sugi Predict

Sugi Predict / Compounds / SCHEMBL3525643

SCHEMBL3525643

SCHEMBL3525643

CCCCCCCCCCCCCCCC(=O)C(OP(=O)([O-])OCC[N+](C)(C)C)[C@H](CO)OC(=O)CCCCCCCC=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ NR5A2 O00482 1/20 0.55
▸ NR5A1 Q13285 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ MAPT P10636 1/20 0.51
▸ ADRA1D P25100 1/20 0.47
▸ PTAFR P25105 1/20 0.47
▸ HTR1D P28221 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ ADRA1B P35368 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ TMEM97 Q5BJF2 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ ESR1 P03372 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ CDC25A P30304 1/20 0.46
▸ AGTR1 P30556 1/20 0.46
▸ AKT1 P31749 1/20 0.46
▸ ADRA1A P35348 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL993163 0.98 SMN1; SMN2 (0.55) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL479222 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL672371 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL37559 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL479388 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL671456 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL479198 0.94 ALDH1A1 (0.60) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL671970 0.93 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL479150 0.93 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL
SCHEMBL14967280 0.93 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013032643-A2 LIPIDS CAPABLE OF CONFORMATIONAL CHANGE AND THEIR USE IN FORMULATIONS TO DELIVER THERAPEUTIC AGENTS TO CELLS DICERNA PHARMACEUTICALS, INC. (US) 2013-03-07 — — WO claimed
EP-1626728-A4 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD (IL) 2009-09-02 — — EP claimed
US-20070099868-A1 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders VASCULAR BIOGENICS LTD. (IL) 2007-05-03 — — US claimed
EP-1626728-A2 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS Vascular Biogenics Ltd. (IL) 2006-02-22 — — EP claimed
WO-2004106486-A2 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD. (IL) 2004-12-09 — — WO claimed
EP-3599899-A1 STABLE DRY POWDERS AND EMULSIONS CONTAINING PROBIOTICS AND MUCOADHESIVE PROTEIN VIRUN, INC. (US) 2020-02-05 — — EP disclosed
EP-3468612-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac AG (DE) 2019-04-17 — — EP disclosed
EP-3468609-A1 CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY CureVac AG (DE) 2019-04-17 — — EP disclosed
EP-3468608-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac AG (DE) 2019-04-17 — — EP disclosed
WO-2018174938-A1 STABLE DRY POWDERS AND EMULSIONS CONTAINING PROBIOTICS AND MUCOADHESIVE PROTEIN VIRUN, INC. (US) 2018-09-27 — — WO disclosed
WO-2017212008-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CUREVAC AG (DE) 2017-12-14 — — WO disclosed
WO-2017212007-A1 CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY CUREVAC AG (DE) 2017-12-14 — — WO disclosed
WO-2017212006-A1 HYBRID CARRIERS FOR NUCLEIC ACID CARGO CUREVAC AG (DE) 2017-12-14 — — WO disclosed
WO-2017049162-A1 COMPOSITIONS FOR PROVIDING AGENTS THAT DEGRADE IN WATER VIRUN, INC. (US) 2017-03-23 — — WO disclosed
WO-2013032643-A2 LIPIDS CAPABLE OF CONFORMATIONAL CHANGE AND THEIR USE IN FORMULATIONS TO DELIVER THERAPEUTIC AGENTS TO CELLS DICERNA PHARMACEUTICALS, INC. (US) 2013-03-07 — — WO disclosed
EP-2193371-A2 METHODS AND DEVICES FOR CONTROLLED MONOLAYER FORMATION Orwar, Owe (SE) 2010-06-09 — — EP disclosed
EP-1626728-A4 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD (IL) 2009-09-02 — — EP disclosed
WO-2009024869-A2 METHODS AND DEVICES FOR CONTROLLED MONOLAYER FORMATION ORWAR OWE (SE) 2009-02-26 — — WO disclosed
EP-1626728-A2 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS Vascular Biogenics Ltd. (IL) 2006-02-22 — — EP disclosed
WO-2004106486-A2 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD. (IL) 2004-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099868-A1 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders ALOX15B, GPX4, ALOX12 SMN1; SMN2 3060/4885NR5A2 1713/4885NR5A1 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.